# Evaluation of Treatment Strategies for Male Prolactin-Secreting Pituitary Neuroendocrine Tumors

## TL;DR

This study evaluates cabergoline treatment for male patients with prolactin-secreting pituitary tumors, finding it effective in most cases.

## Contribution

The study provides insights into cabergoline's efficacy in male prolactin-secreting PitNETs, a less common condition.

## Key findings

- Eight out of nine male patients showed tumor shrinkage and normalized prolactin levels with cabergoline.
- Visual field disturbance was the most common symptom among the patients.
- One patient required surgery after not responding to cabergoline treatment.

## Abstract

Prolactin-secreting pituitary neuroendocrine tumors (PitNETs) are more common in women. Male patients may also have few symptoms and have macroadenomas extending outside the sella turcica. This study aimed to report the results of cabergoline treatment in male patients with prolactin-secreting PitNET. The study included nine male patients aged 26-65 years (median, 46 years) diagnosed with prolactin-secreting PitNETs. The age at onset, prolactin values, tumor size, symptoms, and treatment were assessed. The mean prolactin value at the initial presentation was 2734.6 ng/mL, and the mean maximum tumor diameter was 40.4 mm. Visual field disturbance was the most common symptom (44.4%), followed by headaches (33.3%), asymptomatic symptoms (11.1%), and galactorrhea (11.1%). Eight patients responded to cabergoline treatment with normalization of prolactin levels and tumor shrinkage. One patient did not respond to the cabergoline treatment and required surgical intervention. There were no cases of cerebrospinal fluid leakage. Cabergoline was found to be an effective treatment for male prolactin-secreting PitNETs.